Scarica l'app Stockscreener
0.9398
6.02%
-0.0602
Dopo l'orario di chiusura:
.93
-0.0098
-1.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VTYX Giù?
Forum
Previsione
Ventyx Biosciences Inc Borsa (VTYX) Ultime notizie
Ventyx Biosciences chief scientific officer John Nuss sells $2,019 in shares - Investing.com
VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Stock Traders Purchase Large Volume of Call Options on Ventyx Biosciences (NASDAQ:VTYX) - Defense World
Ventyx boosts advisory board with top scientists By Investing.com - Investing.com South Africa
Ventyx boosts advisory board with top scientists - Investing.com
Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts - GlobeNewswire
Insiders' US$1.26m Investments In Red Following Ventyx Biosciences' US$11m Dip In Market Value - simplywall.st
Ventyx Biosciences stock hits 52-week low at $1.21 amid market challenges - Investing.com
Ventyx Biosciences stock hits 52-week low at $1.28 amid market challenges - Investing.com Australia
Ventyx Biosciences Faces Supply Chain Risks Amidst U.S.-China Tensions and Regulatory Challenges - MSN
Ventyx Biosciences stock hits 52-week low at $1.37 amid market challenges - Investing.com Australia
Rhumbline Advisers Acquires 40,813 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights – VTYX - ACCESS Newswire
Ventyx Biosciences Reports 2024 Financial Results and Progress - TipRanks
Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc.(VTYX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Ventyx Biosciences stock hits 52-week low at $1.41 amid market challenges - Investing.com India
Ventyx Biosciences stock hits 52-week low at $1.41 amid market challenges By Investing.com - Investing.com South Africa
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Ventyx Biosciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVTYX - ACCESS Newswire
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm - ACCESS Newswire
Ventyx Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ventyx Biosciences, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Ventyx Biosciences reports Q4 EPS (41c), consensus (55c) - TipRanks
VTYXVentyx Biosciences, Inc. Latest Stock News & Market Updates - Stock Titan
Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc. (VTYX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Ventyx Biosciences Reports Fourth Quarter and Full Year - GlobeNewswire
Can Ventyx's $252.9M Cash Cushion and 3 Upcoming Trial Readouts Excite Biotech Investors? - StockTitan
Ventyx Biosciences stock hits 52-week low at $1.57 By Investing.com - Investing.com Australia
Ventyx Biosciences stock hits 52-week low at $1.57 - Investing.com India
Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire
Ventyx Biosciences (VTYX) to Release Earnings on Tuesday - Defense World
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
Ventyx Biosciences Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Ventyx Biosciences Announces Presentation of Data from the - GlobeNewswire
Ventyx Biosciences’ VTX958 shows efficacy in Crohn’s Disease - TipRanks
Ventyx reports mixed results in Crohn's disease trial By Investing.com - Investing.com Australia
Ventyx reports mixed results in Crohn's disease trial - Investing.com India
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 - The Bakersfield Californian
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025 - Yahoo Finance
SG Americas Securities LLC Cuts Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):